Liposomal Nanomedicines In Cancer Therapy

As nanocarriers, liposomes have long been studied for their ability to deliver medications to their sites of action while lowering toxicity.Nanotechnology is among the most exciting new technologies of the twenty-first century.Phospholipids give liposomes their form. Anticancer medications, among other medications, can be delivered by liposome encapsulation. Liposomes can include both hydrophilic and hydrophobic medicines. Once closed lipid bilayer vesicles were discovered, the name liposomes was first used in 1960. As medication carriers, liposomes are helpful, but making them using organic solvents calls for sophisticated techniques. Although destroying every cancer cell is a challenge, that can be utilised in cancer treatment. The majority of the time, liposomes are nanosized lipid particles. Although they need sophisticated fabrication techniques involving organic solvents, liposomes are helpful as medication carriers. Given that cancer causes millions of deaths annually, it remains a serious public health concern. These advantages have led to the licensing and effective usage of several liposomal medications in clinics over the last few decades. Liposomes are a promising option for drug delivery and cancer treatment in the realm of nanomedicine because of their ability to retain drugs with different physical and chemical properties. Furthermore, the potential, challenges, and prospective improvements to liposomal medicines for cancer treatment were investigated. This review describes liposome, history, structure, composition, types, preparation methods, evaluation parameters and clinical applications.